de Ridder M, Gouw Z A R, Sonke J J, Navran A, Jasperse B, Heukelom J, Tesselaar M E T, Klop W M C, van den Brekel M W M, Al-Mamgani Abrahim
Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1691-1700. doi: 10.1007/s00405-016-4413-7. Epub 2016 Dec 9.
The objectives is to thoroughly analyze the pattern of failure and oncologic outcome in recurrent oropharyngeal cancer (OPC) after (chemo)radiotherapy and correlate the site of failure to the planned radiation dose. Between January 2010 and April 2014, 57 patients with recurrent OPC after (chemo)radiotherapy were analyzed. Endpoints were pattern of failure and overall survival (OS). Local (LF) and regional failure (RF) were classified as in-field [>50% within gross tumor volume (GTV)], marginal [<50% within GTV but >50% within clinical target volume (CTV)], or out-of-field (>50% outside CTV) recurrences. In the whole group, 70 recurrences were reported. Of the 31 LF, 29 (93.5%) were in-field and 2 (6.5%) were marginal. No out-field LF was reported. Of the 21 RF, 13 RF (62%) were in-field, 6 (28.5%) marginal, and 2 (9.5%) out-of-field recurrences. Forty-three percent of RF was developed in an electively treated neck level, and 2 of them were contralateral. OS at 2 years in recurrent HPV positive, compared to HPV-negative OPC, were 66 and 18%, respectively (p = 0.011). OS was also significantly better in patients that were salvage treatment which was possible (70 vs. 6%, p < 0.001). Median survival after distant failure was 3.6 months. The great majority of LFs were located within the GTV and 43% of RFs developed in an electively treated neck level. The currently used margins and dose recipe and the indication for bilateral nodal irradiation need to be reevaluated. OS was significantly better in recurrent HPV-positive OPC and in patients, where salvage treatment was possible.
目的是深入分析复发性口咽癌(OPC)在(化疗)放疗后的失败模式和肿瘤学结局,并将失败部位与计划的放射剂量相关联。在2010年1月至2014年4月期间,对57例(化疗)放疗后复发性OPC患者进行了分析。终点指标为失败模式和总生存期(OS)。局部失败(LF)和区域失败(RF)分为野内复发(大体肿瘤体积(GTV)内>50%)、边缘复发(GTV内<50%但临床靶体积(CTV)内>50%)或野外复发(CTV外>50%)。在整个队列中,共报告了70次复发。在31例LF中,29例(93.5%)为野内复发,2例(6.5%)为边缘复发。未报告野外LF。在21例RF中,13例(62%)为野内复发,6例(28.5%)为边缘复发,2例(9.5%)为野外复发。43%的RF发生在选择性治疗的颈部区域,其中2例为对侧复发。复发性人乳头瘤病毒(HPV)阳性的OPC患者与HPV阴性患者相比,2年OS分别为66%和18%(p = 0.011)。在可行挽救治疗的患者中,OS也显著更好(70%对6%,p < 0.001)。远处失败后的中位生存期为3.6个月。绝大多数LF位于GTV内,43%的RF发生在选择性治疗的颈部区域。当前使用的边界和剂量方案以及双侧淋巴结照射的指征需要重新评估。复发性HPV阳性的OPC患者以及可行挽救治疗的患者的OS显著更好。